Hylvastam

Sodium Hydrogen Carbonate, the active ingredient in Hylvastam, is an alkalinising agent presented as an intravenous solution for intravenous use. It is employed to correct acid‑base disturbances and to manage elevated serum potassium in clinical settings.

GNH USA supplies Hylvastam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Hylvastam (sodium hydrogen carbonate) is used to address acid–base disorders and electrolyte imbalances. - Metabolic acidosis: restores normal blood pH by providing bicarbonate ions. - Hyperkalemia: promotes intracellular shift of potassium, helping lower serum potassium levels. - Drug overdose (e.g., tricyclic antidepressants): alkalinises urine to enhance drug elimination. - Cardiac arrest resuscitation: supports pH balance during advanced cardiac life support.

Common Side Effects: - Injection site pain or irritation. - Mild hypernatremia. - Transient metabolic alkalosis. - Fluid overload in susceptible patients. - Mild hypertension. - Hypocalcaemia.

Serious or Rare Side Effects: - Severe metabolic alkalosis leading to respiratory depression. - Pulmonary oedema. - Life‑threatening arrhythmias. - Severe hypernatremia with neurological signs. - Anaphylactic reaction. - Marked electrolyte disturbances requiring intensive monitoring.

Before using Hylvastam, consider the following precautions: - Monitor serum electrolytes: check sodium, potassium, calcium, and bicarbonate levels regularly. - Assess acid‑base status: confirm metabolic acidosis before administration. - Adjust dose in renal impairment: reduced clearance may increase risk of alkalosis. - Avoid in congestive heart failure: fluid overload can exacerbate cardiac symptoms. - Use with caution in patients on diuretics: may intensify electrolyte shifts. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Hylvastam may interact with other medications as follows: Major Interactions (Avoid): - Concurrent alkalinising agents (e.g., oral sodium bicarbonate): risk of severe metabolic alkalosis. - Loop diuretics combined with high‑dose bicarbonate: can cause profound electrolyte imbalance. - Calcium carbonate supplements: may precipitate calcium carbonate crystals. Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: altered potassium handling may increase hyperkalaemia risk. - NSAIDs: can impair renal function, affecting bicarbonate clearance. - Insulin therapy: may potentiate intracellular potassium shift, requiring close potassium monitoring.